A Fully Implantable Self Powered Extra Aortic Counterpulsation Device? For Translational Development In Hypertensive Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$901,586.00
Summary
The development of a low cost self-powered cardiac aortic assist device to improve blood flow to the heart and rest of the body. The device is placed on the external surface of the large blood vessel (aorta) leaving the heart and provides gentle counterpulsation to improve blood flow. This aortic cardiac assist device is a therapeutic treatment for early stage heart failure.
The Neonav ECG Tip Location System: Better & Safer Care For Paediatric Intensive Care Patients
Funder
National Health and Medical Research Council
Funding Amount
$879,010.00
Summary
Babies and children can be critically ill. When they need intensive care, thin, flexible tubes (catheters) are placed in their blood vessels to deliver fluids and medications. Despite best efforts, catheters may not reach or move from the correct location inside the patient and the procedures may need to be repeated. Our solution is an innovative medical device that tracks where the catheter is during and after the procedure; this makes care safer and less stressful for the babies and children.
Development Of Endovascular Stents With Proactive Biocompatibility
Funder
National Health and Medical Research Council
Funding Amount
$428,470.00
Summary
Metallic cardiovascular implants, such as stents, used in the treatment of heart disease are not compatible with blood. They cause inflammation at the site of implantation and increase the risk of blood clots forming. We have developed a unique method of binding bioactive protein layers to the surface of metal alloys, and shown a significant improvement in their compatibility. Stents coated using our technology stand to dramatically improve the treatment of cardiovascular disease.
Biocompatible Synthetic Conduits To Treat Vascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$421,818.00
Summary
Clinically available synthetic conduits used in vascular repair and bypass are fundamentally incompatible with the vasculature. They cause inflammation at the site of implantation and increase the risk of blood clots forming. We have developed a unique method of binding bioactive protein layers to the surface of all polymeric materials and have shown a significant improvement in their compatibility. Grafts coated using our technology stand to dramatically improve the treatment of vascular diseas ....Clinically available synthetic conduits used in vascular repair and bypass are fundamentally incompatible with the vasculature. They cause inflammation at the site of implantation and increase the risk of blood clots forming. We have developed a unique method of binding bioactive protein layers to the surface of all polymeric materials and have shown a significant improvement in their compatibility. Grafts coated using our technology stand to dramatically improve the treatment of vascular disease.Read moreRead less
A portable device that can measure glycosylated haemoglobin (HbA1c) in the home will be developed. HbA1c is an important biomarker of the average blood glucose levels over the preceding three months and hence guides a diabetic regarding their blood glucose treatment regime. A 1% decrease in HbA1c levels is associated with a dramatic decrease in chronic health complications from diabetes. The HbA1c meter that will be developed will be able to operate with existing glucose meter technologies.
Optimisation Of A Potent And Fast Acting Antimalarial Class That Is Orally Efficacious In Vivo
Funder
National Health and Medical Research Council
Funding Amount
$683,916.00
Summary
Malaria is a devastating disease that results in 600 000 deaths annually. Current therapeutics used to combat malaria have a limited duration of use in the clinic due to the onset of resistance. We have identified a highly active antimalarial series that we propose to further develop to meet the prerequisites required for partnership with the Medicines for Malaria Venture (MMV) for progression into the clinic.
Prostaglandin D2 (PGD2) is a key driver of asthma and allergic rhinitis. We have developed drug-like compounds that block the synthesis of PGD2 by inhibiting the hematopoietic prostaglandin D2 synthase (HPGD2S) enzyme. This project aims to develop these compounds further to ultimately treat a subset of the asthma population that are not well treated, refractory asthmatics.
Low-Cost Portable Inhalation Therapy Platform For Needle-Free DNA-Based Influenza Vaccination
Funder
National Health and Medical Research Council
Funding Amount
$524,644.00
Summary
Influenza affects a large proportion of the global population and can result in many deaths in a pandemic. A DNA influenza vaccine overcomes the possibility of severe side effects associated with commonly used vaccines based on weakened viruses and can be rapidly produced and easily transported without refrigeration. DNA vaccines are however unstable and difficult to deliver. We propose to address this with a low-cost and portable handheld device which allows the vaccine to simply be inhaled.
Isoform Selective PI3 Kinase Inhibitors For Cancer, Thrombosis And Inflammatory Disease
Funder
National Health and Medical Research Council
Funding Amount
$474,473.00
Summary
Inhibitors of the PI3 kinase family of enzymes have potential as therapeutics in diseases such as cancer, thrombosis and inflammatory disease. In this project the investigators will develop a new class of PI3 kinase inhibitors they have discovered, optimizing their pharmaceutical properties and evaluating them in models of disease. The aim is to develop a candidate for human clinical studies.
Dengue virus is the most important mosquito-borne viral disease, with 2/3 of the world's population at risk. There is currently no treatment available for dengue. Our proposal aims to progress a safe and effective new treatment (4-HPR) against Dengue towards the clinic, generating all the required pharmacokinetic and pre-clinical animal data necessary to progress to a future clinical trial in humans. We will also investigate the use of 4-HPR as a dengue preventative.